title: Could prophylactic monoclonal antibody improve kidney graft survival?
abstract: OBJECTIVE
  This study was designed to evaluate the impact of daclizumab monoclonal antibody on early and late kidney graft survival.
  
  
  METHODS
  From 2007 to 2008, 57 kidney transplant recipients were followed for a mean of 9.3 months. Twenty-three patients received 1 mg/kg daclizumab 24 hours before and 14 days after transplantation. In contrast, 34 patients (controls) did not receive daclizumab. The same immunosuppressive protocol was administered to all participants: oral prednisolone, mycophenolate mofetil, and cyclosporine. Delayed graft function (DGF), acute rejection, prednisolone pulses and/or antithymoglobulin (ATG), cytomegalovirus (CMV) infection, urinary tract infection (UTI), as well as early and late graft function were compared between the two groups.
  
  
  RESULTS
  The mean age in cases and controls was 39.7 and 37.1 years, respectively. The occurrence of DGF was 4% versus 3%; reversible acute rejection, 16% versus 14.5%, and irreversible acute rejection 0% versus 9% (P < .05) for treated versus control groups, respectively. ATG was used in 21% versus 23%, and pulse prednisolone 26% versus 20%, respectively. In case and control groups, the mean creatinine levels were 1.4 mg/dL versus 1.35 mg/dL at discharge. At last follow-up, it was 1.35 mg/dL versus 1.2 mg/dL, respectively. CMV infection occurred in 30% versus 35%, and UTI in 17% versus 19% of treated versus controls, respectively.
  
  
  CONCLUSIONS
  The prophylactic administration of daclizumab improved early graft survival and prevented irreversible acute rejection.
authors.affiliation: Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. gh_pourmand@yahoo.com
authors.forename: G
authors.initials: G
authors.lastname: Pourmand
authors.forename: A
authors.initials: A
authors.lastname: Saraji
authors.forename: S
authors.initials: S
authors.lastname: Salem
authors.forename: A
authors.initials: A
authors.lastname: Mehrsai
authors.forename: M R
authors.initials: MR
authors.lastname: Nikoobakht
authors.forename: M
authors.initials: M
authors.lastname: Taherimahmoudi
authors.forename: M
authors.initials: M
authors.lastname: Rezaeidanesh
authors.forename: A
authors.initials: A
authors.lastname: Asadpour
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D000077561:Daclizumab; D051799:Delayed Graft Function / Q000276:immunology; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology; D011239:Prednisolone / Q000627:therapeutic use; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D003404:Creatinine; D000077561:Daclizumab; D009173:Mycophenolic Acid